Discussion on Study Results in Limited Stage Small Cell Lung Cancer

Study results reveal improved median overall survival and progression-free survival in limited stage Small Cell Lung Cancer patients receiving Duralimab compared to placebo, with further data from Duralimab plus TrimalumaMab arm expected in future analyses.